Atezolizumab

Atezolizumab
Antigen-binding fragment of atezolizumab (blue) in complex with PD-L1 (pink).PDB: 5X8L​.
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPD-L1
Clinical data
Trade namesTecentriq, Tecentriq SC
Other namesMPDL3280A, RG7446
AHFS/Drugs.comMonograph
MedlinePlusa616035
License data
Pregnancy
category
Routes of
administration		Intravenous infusion, subcutaneous
Drug classAntineoplastic agent
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6446H9902N1706O1998S42
Molar mass144612.59 g·mol−1

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma,[9][11] but discontinued for use in triple-negative breast cancer (TNBC).[12] It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).[13]

The most common side effects when used on its own include tiredness, reduced appetite, nausea, vomiting, cough, difficulty breathing, diarrhea, rash, fever, pain in the back, joints, muscles and bones, weakness, itching and urinary tract infection.[10] The most common side effects when used with other cancer medicines include peripheral neuropathy (nerve damage in the hands and feet), nausea, anemia (low red blood cell counts), neutropenia (low white blood cell counts), thrombocytopenia (low platelet counts), rash, tiredness, constipation, reduced appetite, diarrhea, and cough.[10]

Atezolizumab was the first PD-L1 inhibitor approved by the U.S. for bladder cancer. Food and Drug Administration (FDA).[14]

In the European Union, atezolizumab is the first PD-(L)1 cancer immunotherapy for subcutaneous injection.[15]

  1. ^ a b "Tecentriq PI" (PDF).
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  3. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  4. ^ "Regulatory Decision Summary for Tecentriq / Tecentriq SC". Drug and Health Products Portal. 13 March 2024. Retrieved 1 April 2024.
  5. ^ "Details for: Tecentriq". Drug and Health Products Portal. 2 May 2017. Retrieved 1 April 2024.
  6. ^ "Details for: Tecentriq SC". Drug and Health Products Portal. 13 March 2024. Retrieved 1 April 2024.
  7. ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
  8. ^ "Tecentriq 1,200 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). Retrieved 4 March 2020.
  9. ^ a b "Tecentriq- atezolizumab injection, solution". DailyMed. 3 June 2020. Retrieved 31 July 2020.
  10. ^ a b c "Tecentriq EPAR". European Medicines Agency. 29 September 2017. Retrieved 31 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. ^ "FDA grants approval to atezolizumab for alveolar soft part sarcoma". U.S. Food and Drug Administration (FDA). 9 December 2022. Retrieved 20 December 2022.
  12. ^ Madhusoodanan, Jyoti (9 August 2023). "How a controversial US drug policy could be harming cancer patients worldwide". Nature. 620 (7973): 264–267. Bibcode:2023Natur.620..264M. doi:10.1038/d41586-023-02492-x. PMID 37558845. Retrieved 21 August 2023.
  13. ^ Cite error: The named reference GT2015 was invoked but never defined (see the help page).
  14. ^ Cite error: The named reference FDA-BC-2016 was invoked but never defined (see the help page).
  15. ^ "European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types – Company Announcement - FT.com". markets.ft.com. Retrieved 5 March 2024.